Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRXOTCMKTS:QBIOOTCMKTS:RSPIOTCMKTS:SKVI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$0.87-15.9%$1.27$0.78▼$41.50$31.67M1.211.09 million shs1.72 million shsQBIOQ Biomed$0.00$0.00▼$0.03N/A2.222,208 shsN/ARSPICortex Pharmaceuticals$0.00+114.3%$0.00$0.00▼$0.00$1.42M0.34376,901 shs12,001 shsSKVISkinvisible$0.27+51.4%$0.22$0.16▼$0.85$1.44M1.63263 shs175 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals0.00%-19.02%-37.66%-51.05%+86,649,900.00%QBIOQ Biomed0.00%0.00%0.00%0.00%0.00%RSPICortex Pharmaceuticals0.00%+1,400.00%-6.25%-16.67%-48.28%SKVISkinvisible0.00%+51.45%+33.50%-53.97%-64.40%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals0.2004 of 5 stars0.03.00.00.01.80.00.0QBIOQ BiomedN/AN/AN/AN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AQBIOQ Biomed 0.00N/AN/AN/ARSPICortex Pharmaceuticals 0.00N/AN/AN/ASKVISkinvisible 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K67.37N/AN/A$0.29 per share2.99QBIOQ Biomed$280KN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/AN/ASKVISkinvisible$20K72.09N/AN/A($1.86) per share-0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/A7/11/2025 (Estimated)QBIOQ Biomed-$2.05MN/A0.00N/AN/AN/AN/AN/AN/ARSPICortex Pharmaceuticals-$2.10MN/A0.00∞N/AN/AN/AN/AN/ASKVISkinvisible-$570K-$0.10N/A∞N/A-2,780.00%N/A-359.02%N/ALatest QBIO, BDRX, SKVI, and RSPI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SKVISkinvisibleN/A-$0.05N/A-$0.05N/A$0.01 million4/14/2025Q4 2024SKVISkinvisibleN/A$0.08N/A$0.08N/A$0.01 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AQBIOQ BiomedN/AN/AN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/AN/AN/ASKVISkinvisibleN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.011.751.75QBIOQ BiomedN/AN/AN/ARSPICortex PharmaceuticalsN/AN/AN/ASKVISkinvisibleN/A0.010.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%QBIOQ BiomedN/ARSPICortex PharmaceuticalsN/ASKVISkinvisibleN/AInsider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%QBIOQ Biomed28.20%RSPICortex Pharmaceuticals50.03%SKVISkinvisible53.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableQBIOQ Biomed3N/AN/ANot OptionableRSPICortex Pharmaceuticals2949.46 million474.45 millionNot OptionableSKVISkinvisible25.40 million2.54 millionNot OptionableQBIO, BDRX, SKVI, and RSPI HeadlinesRecent News About These CompaniesSkinvisible Delays 10-K Filing Due to Compilation IssuesMarch 31, 2025 | tipranks.comSkinvisible, Inc.: Skinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | finanznachrichten.deSkinvisible Reports Licensee Success in Netherton Syndrome Clinical StudiesJanuary 23, 2025 | accessnewswire.comSkinvisible, Inc. (SKVI)November 16, 2024 | finance.yahoo.comSkinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation DevelopmentOctober 3, 2024 | accesswire.comPromising Data on Transdermal Obesity Formulations Announced by SkinvisibleJuly 11, 2024 | accesswire.comSkinvisible Expands Obesity Patent Application for Transdermal DeliveryJune 24, 2024 | accesswire.comSkinvisible, Inc.: Skinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finanznachrichten.deSkinvisible Submits Innovative Obesity Patent for Advanced Transdermal TreatmentMay 29, 2024 | finance.yahoo.comZHUD Zhuding International LimitedMay 15, 2024 | seekingalpha.comSkinvisible, Inc.: Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finanznachrichten.deSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | finance.yahoo.comSkinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons SyndromeFebruary 14, 2024 | accesswire.comFree weights 362X germier than a toilet seatMay 26, 2023 | mensjournal.comSkinvisible, Inc. (SKVI) Stock Historical Prices & Data - Yahoo FinanceMarch 2, 2023 | finance.yahoo.comSKVI.PK - Skinvisible Inc | Stock Price & Latest News | ReutersSeptember 8, 2022 | reuters.comSkinvisible Inc: Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New DrugJune 6, 2022 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQBIO, BDRX, SKVI, and RSPI Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$0.87 -0.16 (-15.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.40%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.Q Biomed OTCMKTS:QBIOQ BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.Cortex Pharmaceuticals OTCMKTS:RSPI$0.0015 +0.00 (+114.29%) As of 06/20/2025 01:10 PM EasternRespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.Skinvisible OTCMKTS:SKVI$0.27 +0.09 (+51.45%) As of 06/20/2025 02:44 PM EasternSkinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
